In Children, Does Using a Synera Patch Decrease Pain When Injecting Propofol at Anesthesia Induction?

NCT ID: NCT01576770

Last Updated: 2012-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate if the Synera Patch (lidocaine/tetracaine patch), used to numb the skin before IV placement, is effective in reducing pain associated with propofol IV administration when inducing general anesthesia, compared to Gebauer's Ethyl Chloride topical anesthetic skin refrigerant.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Commonly, anesthesiologists inject Propofol, a sleeping medication, intravenously to induce general anesthesia. Propofol injection is associated with pain that can be severe.

The investigators also place a lidocaine/tetracaine skin patch (Synera) to decrease pain associated with IV placement. Because the local anesthetics of the Synera patch diffuse deep underneath the skin, in this study the investigators would like to evaluate whether the application of Synera Patch can decrease the pain associated with propofol injection.

Children will be randomized to receive either the patch or the Ethyl Chloride before the IV placement. A total of 33 patients will be enrolled in each group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain on Propofol IV Injection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ethyl chloride vapocoolant spray

Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.

Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.

Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch.

Group Type ACTIVE_COMPARATOR

Gebauer's Ethyl Chloride

Intervention Type DRUG

Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.

Synera Patch

The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.

Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.

Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride.

Group Type EXPERIMENTAL

lidocaine/tetracaine transdermal patch (NDC 43469-864-01)

Intervention Type DEVICE

70 mg lidocaine / 70 mg tetracaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lidocaine/tetracaine transdermal patch (NDC 43469-864-01)

70 mg lidocaine / 70 mg tetracaine

Intervention Type DEVICE

Gebauer's Ethyl Chloride

Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NDC 43469-864-01 CHLOROETHANE, HYDROCHLORIC ETHER NDC 45951-0123

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, outpatient children, 6-17 years old
* American Society of Anesthesiologist Physical Classification rating of 1 or 2
* Elective procedure requiring general anesthesia at Memorial Herman Hospital, The Medical Center, Houston, Texas

Exclusion Criteria

* Skin disease or infection (on dorsum of hands)
* Allergy to lidocaine or tetracaine
Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ZARS Pharma Inc.

INDUSTRY

Sponsor Role collaborator

The University of Texas Health Science Center, Houston

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Samia Khalil

Professor of Pediatric Anesthesia

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Samia N Khalil, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Texas Health Sciences Center at Houston

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Memorial Herman Hospital

Houston, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Samia N Khalil, M.D.

Role: CONTACT

713.500.6242

Mohammed Ali, M.D.

Role: CONTACT

713.500.6194

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSC-MS-12-0042

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Buffered Local Anesthetic
NCT05757648 COMPLETED PHASE4
Synera Venipuncture Pain
NCT01744197 COMPLETED PHASE2